Takeda shares hit as profits slide

11 May 2022
takeda_corporate_large

Japanese drugmaker Takeda (TYO: 4502) reported a rise in revenue at the end of Japan’s 2021/22 financial year, but saw a significant drop in its profits.

Takeda’s reported revenue rose 11.6% to 3,569 billion yen ($27.51 billion), though its 12-month operating profit slid 9.5% to 460.8 billion yen. The absence of one-time gains seen in fiscal 2021 was to blame for the reduction, the company said.

The profit figure compares with Takeda’s earlier estimate of 515 billion yen and a consensus forecast of 509 billion yen from a Refinitiv poll of 15 analysts .Looking ahead, Takeda estimated that the current fiscal year's operating profit would hit 520 billion yen, an increase of nearly 13%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical